This is a repository copy of Design, Synthesis and Conformational Analyses of Bifacial Benzamide Based Foldamers.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/92887/

Version: Accepted Version

Article:

https://doi.org/10.1039/C5RA20451H

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Design, Synthesis and Conformational Analyses of Bifacial Benzamide Based Foldamers

Silvia Rodriguez-Marin, a, b Natasha S. Murphy, a, b Helena J. Shepherd c and Andrew J. Wilson a, b

The design, synthesis and conformational analyses of novel backbones represents a key focus of research that underpins efforts to exploit foldamers (i) in a biological setting e.g. as inhibitors of protein-protein interactions (PPIs) and (ii) for the purposes of constructing functional architectures that adopt defined tertiary and quaternary folds. The current manuscript addresses a need to develop aromatic oligoamide backbones that are regiospecific in terms of backbone connectivity and/or functionalized on more than one face. We describe the design, synthesis and comparative conformational analyses of foldamers derived from 2-, 3- and 2,5-O-alkylated derivatives of para-aminobenzoic acid, and, derived from 2-3- and 2,5-O-alkylated derivatives of 1,4-diaminobenzene/terephthalic acid monomers. Analysis of the accessible conformational space for these oligomers indicates that despite different connectivity they can adopt conformations that position side chains in a manner that mimics the \( i, i + 3, i + 4 \) of an \( \alpha \)-helix.

Introduction

Protein-protein interactions (PPIs) are considered difficult targets for drug discovery due to their large and moderately convex surfaces, and the availability of fewer “obvious” well-defined binding sites when compared to classical enzymes and receptors. Among the wide range of PPI recognition motifs, the \( \alpha \)-helix is the most common secondary structure in nature and thus represents a good generic template for inhibitor design. The proteomimetic approach utilises suitably functionalized non-peptidic foldamers (oligomers that adopt well defined conformations) to topographically mimic the spatial orientation of the key recognition residues on the native \( \alpha \)-helix surface (Fig. 1a). Most of these scaffolds mimic the \( i, i + 4 \) and \( i + 7 \) residues on a single face. In particular oligobenzamides have been described as effective proteomimetics by our group and others, they may be accessed through robust modular syntheses and, as is typical for aromatic oligoamide foldamers, adopt reasonably predictable conformations. Most published studies focus on the design of oligobenzamides mimicking the key residues located on one face of the \( \alpha \)-helix; however, there are also examples of these scaffolds mimicking more than one face. In the context of foldamer synthesis and structure, the construction of backbones functionalised with different side-chains on multiple faces of the scaffold represents an as yet unrealised approach to achieve control over secondary conformation and higher order tertiary/quaternary organisation. Similarly, there is an obvious need for PPI inhibiting helix mimetics that target more than one face of an interaction, such as the case of the estrogen receptor (ER), a ligand-activated transcription factor that plays a key role in the development of certain cancers in response to binding with its natural ligand, ER undergoes a conformational change to promote recruitment of co-regulators, thereby up- or down-regulating the expression of specific genes.

The nuclear receptor box is an alpha helical LXXLL motif (where L is leucine and X any amino acid), which acts as a recognition element between co-activators and their receptors (Fig. 1b). Direct inhibition of the receptor/co-activator protein-protein interaction, not only using helix mimetics is of potential therapeutic interest as an alternative to the use of competitive inhibitors for the ligand binding site. Herein, we introduce two bifacial proteomimetic scaffolds; bis-benzamide and \( N \)-(4-aminophenyl)terephthalamic as novel foldamers designed as tools to (a) enhance our understanding of aromatic oligoamide foldamer conformation and (b) ligands that could mimic the key side chains at \( i, i + 3, i + 4 \) positions of \( \alpha \)-helices that participate in PPIs mediated by such a side chain constellation. A comprehensive analysis of the different scaffolds reveals that different combinations of monomers lead to a plethora of side chain spatial relationships which effectively mimic the intended \( \alpha \)-helix side-chains.

Results and discussion

Figure 1. (a) Bifacial helix mimetics as inhibitors of PPIs (steroid ligand in orange, ER in purple, \( \alpha \)-helix containing co-activator in red and key side chain residues represented as coloured circles). (b) Crystal structure of the ER\( \alpha \) (in purple) bound to an LXXL co-activator motif (in red) (PDB ID: 3ERD) (charge clamp shown in green)
A first generation of scaffold 1-4 (Fig. 2) was designed using the modular oligobenzamide synthetic methodology previously reported by our group (Scheme S2 and S3). Combinations of 3-O-alkylated, 2-O-alkylated and 2,5-O-dialkylated monomers were used to obtain a regioisomeric set of compounds for conformational analyses. The regioisomer of compound 2 could not be obtained due to unsuccessful coupling between methyl 4- amino-2,5-diisobutoxybenzoate and 4-nitro-2-isobutoxybenzoic acid under multiple conditions. The tetrasubstituted scaffold (4) was also synthesised to explore the role of a 4<sup>th</sup> side chain in helix mimicry.

A novel second generation scaffold was designed based on a N-(4-aminophenyl)terephthalamidic acid backbone, where the central amide bond is inverted in comparison with the bis-benzamide scaffold. The dimer is formed from a para-phenylenediamine monomer linked to a terephthalate monomer through an amide bond. The backbone can be functionalized at different positions using a variety of O-alkylated monomers. A convergent synthetic methodology was developed to provide the monomeric building blocks (Scheme 1). Noteworthy features of the monomer syntheses include: (i) the use of a Curtius rearrangement to convert monomer 6 to 7 rendering this synthetically efficient for both building blocks (ii) the use of a common starting material to access monomers 9 and 10 for construction of different regioisomers (see below). Note also that no N-alkylation was observed on transformation of 8 to 9. For monosubstituted alkoxy derivatives of terephthalic acid, it was necessary to perform a sequence of protecting group manipulations.

To effect amide bond formation, the acyl chloride of the di-acid monomer 6 was obtained using thionyl chloride before coupling to its amino-monomer partners 9 or 10 (Scheme 2). By using an excess of the di-acid 6 it was possible to bias the product distribution towards the monoamide. The final products 14<sub>ba</sub> and 14<sub>bb</sub> were obtained by hydrogenation of the nitro group or hydrolysis of the Fmoc group respectively. Due to oxidation upon exposure to air, the di-amine derivative of compound 7 was obtained through in situ Boc deprotection and direct reaction with the acid chloride derivative of 12 or 13; these were obtained by in situ activation using Gho...
Scheme 2. Synthesis of minimal N-(4-aminophenyl)terephthalamidic foldamers.

An X-ray crystal structure of compound 1 reinforces this result with NH to O distances of 2.007 and 2.223 Å respectively for the S(6) and S(5) H-bonded rings (Fig. 3c). Intriguingly, similar NMR analyses for compound 4 were indicative only of pseudo-six-membered hydrogen bonding in solution. Compounds 14aa, 14bb form pseudo-five- or six-membered hydrogen-bonded rings as expected whereas 14ab (Fig. 3b) and 14ba showed evidence of only pseudo-six-membered intramolecular hydrogen bonded ring formation in solution. These results are supported by H/D exchange experiments performed on compounds 1-3, 14aa and 14bb as models of the three types of intramolecular hydrogen bonding interaction (Fig. 3d, Table 1 and S1). The rate of exchange is entirely consistent with that which is observed for S(6) type hydrogen bonded rings for the regiosomeric oligomers derived from 2-O-alkoxy-4-aminobenzoic acid and suggests the different electronic structure of the 2,5-dialkoxyterephthalamide monomer does not dramatically affect the strength of hydrogen-bonding. Molecular modelling was also performed on all the compounds (Fig 3a). The lowest energy conformations all adopt an extended structure, where the amide bond is trans. The low energy conformations for each compound are consistent with those that are accessible in solution phase according to the NOESY data. The nature of the structure permits the superimposition in both parallel and antiparallel N-to-C orientation with respect to an α-helical peptide. Accordingly, both alignments were analysed using an ERα co-activator sequence. The match was assessed on the basis of the RMSD between α-carbons on the helix and oxygen atoms on the foldamer together with an evaluation on the quality of orientation with respect to the helical axis of the peptide (Table 2 and ESI for details). For compounds 1-3, 14aa and 14bb, in the poses presenting the best overlay, the three side chains overlap reasonably well with the leucine residues at positions $i$, $i+3$ and $i+4$ of the co-activator helix (Fig. 3a for 14aa and Fig. S5-11 for other dimers) and the distances between the oxygens of the dimers match the distance between the α-CH of those residues. Compounds 14ab and 14ba, matched less well in terms of alignment with the helical backbone.

Table 1. Kinetic constants and $t_{1/2}$ based on H/D exchange in 10% CD$_3$OD/CDCl$_3$.

<table>
<thead>
<tr>
<th>$k_{HD}$ (min$^{-1}$)</th>
<th>$t_{1/2}$ (min)</th>
<th>H bonding</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6.7857 x 10$^{-4}$ ± 0.00000093</td>
<td>1021.5 ± 14</td>
</tr>
<tr>
<td>2</td>
<td>0.01485 ± 0.000017</td>
<td>46.7 ± 0.5</td>
</tr>
<tr>
<td>14ba</td>
<td>0.00305 ± 0.000005</td>
<td>228 ± 3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Compound</th>
<th>Alignment</th>
<th>RMSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Antiparallel</td>
<td>1.322</td>
</tr>
<tr>
<td>2</td>
<td>Parallel</td>
<td>1.625</td>
</tr>
<tr>
<td>3</td>
<td>Antiparallel</td>
<td>2.084</td>
</tr>
<tr>
<td>14aa</td>
<td>Antiparallel</td>
<td>1.038</td>
</tr>
<tr>
<td>14ab</td>
<td>no good alignment</td>
<td>1.622</td>
</tr>
<tr>
<td>14ba</td>
<td>no good alignment</td>
<td>1.027</td>
</tr>
<tr>
<td>14bb</td>
<td>Parallel</td>
<td>2.046</td>
</tr>
</tbody>
</table>

* where N and C termini of the benzamide and helix match, they are defined as being parallel and where they oppose, they are defined as being antiparallel.
Figure 3. (a) Preferred conformation and intramolecular hydrogen-bonding interactions of the compounds 1-3 and 14 supported by molecular modelling, 2D NMR studies and H/D exchange experiments. Distances and angles between side chains (green and black respectively), H-bonds (dashed red line) and free rotation axes (red arrow) are shown.

Docking studies using the lowest energy conformation of each foldamer were also performed to ascertain the extent to which they might act as ERα/co-activator inhibitors (see ESI). The results from
the docking analyses reveal binding poses that display favourable interaction of the foldamers 1-3 and 14 with the co-activator binding groove. Electrostatic interactions are observed for both termini of the foldamer. However, in all cases only one of these involves the precise “charge clamp” residues from ER exploited by co-activator ligands. Shown in Fig. 4b is a good pose for 14aa; the three hydrophobic side chains of the foldamer occupy the hydrophobic space normally occupied by the co-activator peptide. The terminal carboxamide and aniline groups of the dimer are suitably positioned to form electrostatic interactions with glutamic acid(542) and glutamine 372 (rather than lysine362) in the region of the “charge clamp”. This behaviour is reproduced for the other compounds (e.g. Fig S12 for 1).

**Figure 4.** (a) Overlay of compound 14aa with a co-activator peptide. Co-activator residues are in dark colours and helix mimetic residues are in light colours (side and top views are given). (b) Potential binding mode of compound 14aa in the ER co-activator-binding groove with the native helix in transparent red.

To perform a preliminary assessment of the ability of these compounds to act as PPI inhibitors, we carried out fluorescence polarisation competition assays for three nuclear receptor/co-activator interactions (ERα/SrcBox2, ERβ/Src1B2 and RXRα/D22), however the compounds were not sufficiently potent to show a significant effect in these assays. Future studies will focus on the synthesis of libraries bearing different side-chains and terminal groups together with a broader array of biophysical and cellular assays to explain this observation and identify potent inhibitors.

**Conclusions**

In conclusion, we have described the design, synthesis and comparative structural/ conformational analyses of two minimal bifacial foldamer scaffolds, using for first time a comparative structural/ conformational analyses of two minimal aromatic benzamide scaffolds as components of proteomimetic inhibitors of PPIs.

**Acknowledgements**

This work was supported by the European Research Council (ERC-StG-240324) and [ERC-PoC-632207]. We thank Prof Luc Brunsveld and Marcel Scheepstra (Technische Universiteit Eindhoven) for assistance in performing preliminary ER/ co-activator assays. We also thank Dr Chris Pask (University of Leeds) for assistance with Crystallographic data deposition.

**References**


*This journal is © The Royal Society of Chemistry 20x*